title: Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
abstract: OBJECTIVE
  This analysis was conducted to evaluate the efficacy and safety of icotinib based regimens in treating patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of icotinib-based regimens with regard to response and safety for patients with NSCLC were identified using a predefined search strategy. Pooled response rates of treatment were calculated.
  
  
  RESULTS
  With icotinib-based regimens, 7 clinical studies which including 5,985 Chinese patients with NSCLC were considered eligible for inclusion. The pooled analysis suggested that, in all patients, the positive reponse rate was 30.1% (1,803/5,985) with icotinib-based regimens. Mild skin itching, rashes and diarrhea were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment-related death occurred in patients treated with icotinib-based regimens.
  
  
  CONCLUSIONS
  This evidence based analysis suggests that icotinib based regimens are associated with mild response rate and acceptable toxicity for treating Chinese patients with NSCLC.
authors.affiliation: Department of Oncology, The Second Hospital of Nantong City, Nantong, China E-mail : huangxinen06@163.com.
authors.forename: Bing
authors.initials: B
authors.lastname: Shi
authors.forename: Xiu-Bing
authors.initials: XB
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Xu
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D043844:Crown Ethers / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib